ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
The global antibodies contract manufacturing market is estimated to be valued at USD 19.61 Bn in 2024 and is expected to reach USD 38.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10% from 2024 to 2031. Antibodies are glycoproteins produced by B cells of the immune system to neutralize pathogens like bacteria and viruses. Contract manufacturing of antibodies has emerged as an outsourcing strategy adopted by biotech and pharmaceutical companies to develop and produce antibodies on a commercial scale. Factors such as hefty R&D investments required for antibody development, lack of in-house production capabilities, and focus on core competencies have boosted the demand for contract services. Moreover, continued advancements in cell line engineering and purification techniques have enabled contract manufacturers to provide high quality, consistent antibodies in large quantities. This has solidified antibodies contract manufacturing as an established business model worldwide.
Market Dynamics:
The global antibodies contract manufacturing market is driven by factors such as rising R&D expenditure of biopharmaceutical companies, advancement of monoclonal antibody therapeutics, growing focus on core competencies, and outsourcing of non-core activities. However, factors such as stringent regulatory processes and quality specifications, potential risks of technology transfer and capacity constraints pose challenges for smooth operations. On the brighter side, the market sees lucrative opportunities owing to increasing demand for bio-better and cost-effective antibodies, progress in molecular engineering tools, and emergence of developing biologics industry in countries like India and China.
Key Features of the Study:
- This report provides in-depth analysis of the global antibodies contract manufacturing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players Lonza Group, WuXi Biologics, Catalent, Inc., Fujifilm Diosynth Biotechnologies, Rentschler Biopharma SE, Charles River Laboratories, Samsung Biologics, AbbVie Contract Manufacturing, Merck KGaA, BioNTech SE, Amgen, Inc., Genentech, Inc., Takeda Pharmaceutical Company, Celerion, and Avid Bioservices, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antibodies contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibodies contract manufacturing market
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on 'Global Antibodies Contract Manufacturing Market' - Global forecast to 2031
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
